

Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children

Nadine G. Andersson,^{1,2,3} Veerle Labarque,⁴ Mutlu Kartal-Kaess,⁵ Fernando Pinto,⁶ Torben Stamm Mikkelsen,⁷ Rolf Ljung² and PedNet Study Group members⁸

¹Center for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden; ²Department of Pediatrics, Skåne University Hospital, Lund, Sweden; ³Department of Clinical Sciences and Pediatrics, Lund University, Lund, Sweden; ⁴Department of Pediatrics, Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium; ⁵Division of Pediatric Hematology and

Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland; ⁶Royal Hospital for Children, Glasgow, UK; ⁷Department of Pediatric Oncology and Hematology, University Hospital, Aarhus, Denmark and ⁸Pednet Haemophilia Research Foundation, Barn, the Netherlands

Correspondence:

N. G. ANDERSSON - nadine.gretenkort_andersson@med.lu.se

<https://doi.org/10.3324/haematol.2023.284095>

Supplement:

Table S1:

Contributors: The PedNet Study group members and centers

Europe

- MT Alvarèz Román, Unidad de Coagulopatías, Hospital Universitario La Paz, Madrid, Spain
- O Benitez Hidalgo, Unitat Hemofilia, Hospital Vall d'Hebron, Barcelona, Spain
- J Blatny, Department of Paediatric Haematology, Children's University Hospital, Brno, Czech Republic
- M Bührlen, Gesundheit Nord, Klinikum Bremen Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany
- M Carvalho, Immunohemotherapy Department, Congenital Coagulopathies Reference, Centro Hospitalar e Universitário São João, E.P.E., Porto, Portugal
- G Castaman, Department of Oncology Careggi University Hospital, Florence, Italy
- H Chambost, APHM, La Timone Children's Hospital, Center for Bleeding Disorders & Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France
- A Rosa Cid, Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- C Escuriola-Ettingshausen, HZRM Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf, Germany
- K Fischer, Van Creveld Kliniek, University Medical Center Utrecht, Utrecht, The Netherlands
- C Van Geet, Catholic University of Leuven, Campus Gasthuisberg, Service of Pediatric Haematology, Leuven, Belgium
- N Gretenkort Andersson, Department of Clinical Sciences, Lund University, Lund; Department of Pediatrics and Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden
- M Kartal-Kaess, Division of Pediatric Hematology & Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland
- H Knudsen, Oslo University Hospital HF, Oslo, Norway
- C Königs, University Hospital Frankfurt, Department of Paediatrics and Adolescent Medicine, Frankfurt, Germany
- M Koskenvuo, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- R Ljung, Department of Clinical Sciences - Paediatrics, Lund University, Lund, Sweden
- C Male, Department of Paediatrics, Medical University Hospital of Vienna, Vienna, Austria
- T Stamm Mikkelsen, Department of Pediatrics, University Hospital of Aarhus at Skejby, Aarhus, Denmark
- A Molinari, Dipartimento di Ematologia ed Oncologia, Unità Trombosi ed Emostasi, Ospedale Pediatrico Giannina Gaslini, Genova, Italy
- J Motwani, Department of Haematology, The Children's Hospital, Birmingham, UK
- B Nolan, Department of Paediatric Haematology, Our Lady's Children's Hospital for Sick Children, Crumlin, Dublin, Ireland
- R d'Oiron, Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, et HITH UMR_S1176 INSERM, Hopital Bicêtre, APHP Université Paris Saclay, Le Kremlin Bicêtre, Franc
- J Oldenburg, Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Germany
- M Olivieri, Dr. V. Hauner Children's Hospital, University of Munich, Munich, Germany

- C Oudot, Centre Regional d'Hemophilie, Centre Hospitalo Universitaire, Toulouse, France
- H Pergantou, Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece
- F Pinto, Department of Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
- S Ranta, Pediatric Coagulation Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
- E Zápotocká, Department of Pediatric Hematology and Oncology, Prague, Czech Republic
- Royal Hospital for Sick Children, Edinburgh, UK*
- Universitäts-Klinik für Kinder- und Jugendheilkunde, Graz, Austria*
- Hemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children, London, UK*
- Maggiore Hospital Policlinico, A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan, ITALY*
- Hospital General Unidad de Hemofilia, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain*

* No longer participating as PedNet center

Israel

- G Kenet, National Hemophilia Center Sheba Medical center, Tel Hashomer & Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Israel

Canada

- M Carcao, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada
- G Rivard, Division of Hematology/Oncology, Hôpital St Justine, Montréal, Canada

Table S2: Inhibitor development, including high-responding and low-responding inhibitors in percentage, CI and ratio (high-responding versus low-responding inhibitors).

	Inhibitor incidence %, 95%CI	HR inhibitor incidence %, 95%CI	LR inhibitor incidence %, 95%CI	Ratio: HR versus LR Ratio, CI
Inv22 <i>n=573</i>	42.7% 38.6-46.7	28.5% 24.8-32.2	14.2% 11.3-17.0	2.01* 1.71-2.39
Frameshift <i>n=184</i>	22.8% 16.8-28.9	11.4% 6.8-16.0	11.4% 6.8-16.0	1.0 0.56-1.79
Missense <i>n=135</i>	6.7% 2.5-10.9	2.2% 0.0-4.7	4.4% 0.9-7.9	0.5 0.13-1.95
Nonsense <i>n=102</i>	31.4% 22.4-40.3	26.5% 17.9-35.0	4.9% 0.7-9.0	5.4 * 2.17-13.5
Splice site <i>n=36</i>	30.6% 15.5-45.6	19.4% 6.5-32.4	11.1% 0.8-21.4	1.75 0.5-5.47
Large deletions <i>n=32</i>	56.2 39.0-73.4	46.9% 29.6-64.2	8.3% 0.0-19.5	5.6 * 1.6-16.9
Inversion 1 <i>N=17</i>	23.5% 3.4-43.7	23.5% 3.4-43.7	0%	n.a.

*Significant ratio high-responding versus low-responding inhibitors.